HAMBURG, Germany, March 22, 2010 – Evotec AG announced it has entered into a collaboration with Active Biotech AB to identify small-molecule modulators of a priority biological target, selected by the latter company, involved in immune disorders and cancer.
The former company, a novel small-molecule drugs discovery and development company, will use its technologies in assay development, high-throughput screening and surface plasmon resonance screening for the identification and validation of novel hits. It will screen its Lead Discovery Library, a small-molecule collection, to maximize the probability of finding medicinal chemistry starting points.
Active Biotech, of Lund, Sweden, is an autoimmune and inflammatory diseases and cancer biotechnology company.
For more information, visit: www.evotech.com